TB Alliance, Pharmaceutical Partner Begin Clinical Trial For XDR-TB Treatment Regimen In South Africa

Center for Global Health Policy’s “Science Speaks”: First all-oral XDR-TB drug regimen trial launches in South Africa
Rabita Aziz, policy research coordinator for the Center for Global Health Policy, discusses the start of a TB treatment clinical trial in South Africa, writing, “The TB Alliance Wednesday announced the launch of the first clinical trial testing an all-oral regimen to treat extensively drug-resistant tuberculosis. With a three drug combination, the Nix-TB regimen trial seeks to cure patients within six to nine months…” (5/14).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.